Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-2)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 242 participants.

Also called NCT04274049

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 242 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04274049
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04274049. Randomized; quadruple masking; primary purpose treatment. Start 2019-08-28 (actual); primary completion 2023-12-23 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-2)
Condition
Arterial Occlusive Disease
Condition
Ischemia
Condition
Ulcers
Condition
Peripheral Vascular Disease
Intervention (Genetic)
NL003
Intervention (Other)
Normal Saline
Lead sponsor
Beijing Northland Biotech. Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04274049
Content hash
665b0e62d35360940ab9c887c74e33c32bd12ce89b98fd21596e8d268c594892